stockrow
Friday 6 November 2026
Export RXRX’s income statement to Excel — free account
Recursion Pharmaceuticals, Inc.
RXRX Healthcare Biotechnology
Recursion Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.7 million, up 26.9% from fiscal 2024.
- Revenue
- +258.5%
- EPS
- +39.1%
- Free cash flow
- +33.8%
- Total debt
- −99.2%
Quarter to September 2026, against a year earlier
3.59
0.09
+2.57%
Follow RXRX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
32.87 | 35.62 | 24.47 | 24.51 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(28.97) | (18.44) | (20.04) | (39.72) | |
P/B ratio |
2.48 | 2.14 | 1.59 | 1.62 | |
Price to Tangible BV |
4.76 | 4.14 | 2.85 | 2.78 | |
EV/Sales |
24.71 | 25.66 | 14.64 | 14.62 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(5.43) | (4.02) | (3.03) | (2.94) | |
EV/FCF |
(5.36) | (3.97) | (2.96) | (2.87) | |
Quick Ratio |
4.80 | 4.72 | 5.19 | 5.23 | |
Current Ratio |
5.01 | 5.03 | 5.47 | 5.50 | |
Net Debt/EBITDA |
5.22 | 4.68 | 6.00 | 8.31 | |
Debt/Assets |
0.01% | 0.39% | 0.54% | 0.65% | |
Debt/Equity |
0.00 | 0.01 | 0.01 | 0.01 | |
Asset Turnover |
0.05 | 0.04 | 0.05 | 0.05 | |
Operating CF/Net income |
0.65 | 0.81 | 0.69 | 0.43 | |
Capex/Depreciation |
(0.02) | (0.11) | (0.02) | (0.06) | |
Research and Development Expense of Revenue |
534.29% | 1,168.37% | 1,358.10% | 269.96% | |
Selling, General and Administrative Expense of Revenue |
175.51% | 541.50% | 534.47% | 94.71% | |
Intangible Assets out of Total Assets |
0.36 | 0.37 | 0.34 | 0.32 | |
Share Based Compensation of Revenue |
124.13% | 254.21% | 343.25% | 66.87% | |
Graham Net Nets |
0.13 | 0.16 | 0.24 | 0.26 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(21.77%) | (28.34%) | (39.09%) | (36.19%) | |
Free Cash Flow Yield |
(14.02%) | (18.13%) | (20.19%) | (20.79%) | |
Revenue per Share |
0.03 | 0.01 | 0.01 | 0.08 | |
Operating CF per Share |
(0.14) | (0.20) | (0.15) | (0.10) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.14) | (0.20) | (0.15) | (0.11) | |
Cash per Share |
1.02 | 1.03 | 1.25 | 1.67 | |
Shareholders Equity per Share |
1.67 | 1.72 | 1.94 | 2.53 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.67 | 1.72 | 1.94 | 2.53 | |
Free Cash Flow |
(77.81) | (107.91) | (81.44) | (47.32) | |
Working Capital |
493.10 | 483.58 | 579.86 | 665.14 | |
Capital Expenditures |
(0.41) | (1.96) | (0.34) | (1.24) | |
Net Current Asset Value |
300.12 | 305.80 | 394.80 | 469.58 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.26 | 0.05 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
27.99 | 18.00 | 29.85 | 36.91 | |
Average Payables |
15.16 | 15.99 | 22.72 | 19.87 | |
Average Assets |
1,310.62 | 1,257.51 | 1,322.38 | 1,461.36 | |
Average Common Equity |
976.38 | 917.07 | 979.36 | 1,082.82 |
Columns are period end dates · fundamentals updated 5 Nov 2026